https://doi.org/10.55788/f0cce75b
“Patients with SABI lack decisional capacity,” said Dr Nawfel Ben-Hamouda (Lausanne University Hospital, Switzerland). “So how can we go about the shared decision-making process?” Dr Ben-Hamouda explained that ‘goal-concordant care’ is to understand a patient’s individual goals and values and to align medical treatment decisions with these goals. The current study compared the alignment between the patient’s wishes and the level of care that was received, by analysing the patient’s medical documentation, the perspective of the patient’s surrogates/family members, and the perspective of the clinicians [1]. The included patients with SABI (n=110) were followed for 6 months.
Surrogates appeared to be more inclined than clinicians to think that the patient would want to receive life-prolonging care by certain measures, excluding resuscitation, whereas doctors and nurse clinicians were more inclined to think that the patient would want to receive life-prolonging care by all medically indicated measures, displaying a first discordance between perspectives. Furthermore, clinical caretakers were more frequently unsure about the goals of the patient than the family members. Finally, the study showed that 46% of the family members’ decisions were influenced by prognostic scores, suggesting that prognostic scores may be valuable tools to improve goal-concordant care.
- Behaghel G, et al. Prognostic scoring and goal-concordant care after severe acute brain injury: a mixed-method study. 10th EAN Congress, 29 June–2 July 2024, Helsinki, Finland.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Changing treatment landscape in myasthenia gravis Next Article
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease? »
« Changing treatment landscape in myasthenia gravis Next Article
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease? »
Table of Contents: EAN 2024
Featured articles
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Treatment escalation and de-escalation in late-onset MS
Diagnostics and Disease Management in Neurology
What is the value of transcranial ultrasound for diagnosing Parkinson’s disease?
How to achieve goal-concordant care in severe acute brain injury?
Changing treatment landscape in myasthenia gravis
Stroke and Vascular Events
High risk for recurrent vascular events in young stroke patients
Anticoagulation or antiplatelet as secondary prevention for cancer-related strokes?
Multiple Sclerosis
Treatment escalation and de-escalation in late-onset MS
How different are late onset and adult onset MS really?
Advances in Neurostimulation
Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease
Spinal cord stimulation for chronic pain: state-of-affairs in 2024
Innovations in VNS and DBS for refractory epilepsy
Genetic and Molecular Therapies
Extended success for N-acetyl-L-leucine in Niemann-Pick disease type C
Therapeutic advancement in spinal muscular atrophy
Therapeutic advancement in Pompe disease
Neurological Risk Factors and Predictive Tools
Under investigation: Opioid use and the risk for dementia
Novel tool to predict outcomes in anti-NMDAR encephalitis
Related Articles
December 4, 2023
Rate of grey matter brain atrophy accelerates after menopause
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com